Atossa Genetics (NASDAQ:ATOS) Stock Crosses Below 200-Day Moving Average – Here’s Why

Atossa Genetics Inc. (NASDAQ:ATOS)’s stock price passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $7.14 and traded as low as $4.65. Atossa Genetics shares last traded at $4.85, with a volume of 46,768 shares changing hands.

Wall Street Analyst Weigh In

Several brokerages recently commented on ATOS. HC Wainwright increased their price target on Atossa Genetics to $25.00 and gave the company a “buy” rating in a research report on Thursday, March 26th. Ascendiant Capital Markets decreased their target price on shares of Atossa Genetics from $120.00 to $24.00 and set a “buy” rating for the company in a research note on Friday, April 10th. Finally, Weiss Ratings upgraded shares of Atossa Genetics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 22nd. Two research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. According to MarketBeat, Atossa Genetics has an average rating of “Hold” and an average price target of $24.50.

Atossa Genetics Stock Up 3.2%

The business has a fifty day moving average of $5.24 and a 200 day moving average of $7.14. The firm has a market cap of $41.76 million, a P/E ratio of -1.51 and a beta of 1.24.

Atossa Genetics (NASDAQ:ATOS) last released its quarterly earnings data on Friday, May 8th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.99) by ($0.12). Research analysts expect that Atossa Genetics Inc. will post -4.41 EPS for the current year.

Hedge Funds Weigh In On Atossa Genetics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. XTX Topco Ltd raised its holdings in Atossa Genetics by 581.2% in the 4th quarter. XTX Topco Ltd now owns 169,261 shares of the company’s stock valued at $100,000 after acquiring an additional 144,412 shares during the period. &PARTNERS acquired a new position in shares of Atossa Genetics in the fourth quarter valued at approximately $25,000. Graham Capital Management L.P. grew its position in shares of Atossa Genetics by 27.8% in the fourth quarter. Graham Capital Management L.P. now owns 211,369 shares of the company’s stock valued at $125,000 after purchasing an additional 45,923 shares during the last quarter. State Street Corp increased its stake in shares of Atossa Genetics by 31.2% during the fourth quarter. State Street Corp now owns 596,485 shares of the company’s stock worth $352,000 after purchasing an additional 141,990 shares during the period. Finally, Renaissance Technologies LLC increased its stake in shares of Atossa Genetics by 33.2% during the fourth quarter. Renaissance Technologies LLC now owns 2,062,838 shares of the company’s stock worth $1,217,000 after purchasing an additional 514,175 shares during the period. 12.74% of the stock is owned by institutional investors.

Atossa Genetics Company Profile

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.